Alaunos Therapeutics (TCRT) Return on Capital Employed (2010 - 2026)
Alaunos Therapeutics (TCRT) reported Return on Capital Employed of 226.56% for Q1 2026, up 7609.0% on a YoY basis from 2.94% in Q1 2025, and down 35.78% quarter-over-quarter from 166.86% in Q4 2025.
Alaunos Therapeutics (TCRT) Return on Capital Employed (2010 - 2026) Analysis & Trends
Alaunos Therapeutics has reported Return on Capital Employed for 17 years, with the latest figure at 226.56% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 7609.0% year-over-year to 226.56%; the trailing twelve-month figure through Mar 2026 stood at 226.56% (up 7609.0% YoY), and the FY2025 full-year result was 206.35%, down 10645.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 226.56%, down from 166.86% in the prior quarter.
- The five-year high for Return on Capital Employed was 83.63% in Q4 2022, with the low at 445.63% in Q1 2024.
- Historically, Return on Capital Employed has averaged 204.51% across 5 years, with a median of 171.49% in 2025.
- Annual changes were most pronounced in 2024 — Return on Capital Employed tumbled 35579 bps — and 2025, when it jumped 26714 bps.
- Alaunos Therapeutics' Return on Capital Employed stood at 83.63% in 2022, then plunged by 244 bps to 288.07% in 2023, then soared by 32 bps to 195.61% in 2024, then gained by 15 bps to 166.86% in 2025, then sank by 36 bps to 226.56% in 2026.
- The last three Return on Capital Employed figures came in at 226.56% (Q1 2026), 166.86% (Q4 2025), and 123.11% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Alaunos Therapeutics | 4.31 Mn | 3.95 Mn | - | -226.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -226.56% |
| Dec 31, 2025 | -166.86% |
| Sep 30, 2025 | -123.11% |
| Jun 30, 2025 | -171.49% |
| Mar 31, 2025 | -302.65% |
| Dec 31, 2024 | -195.61% |
| Sep 30, 2024 | -365.18% |
| Jun 30, 2024 | -438.62% |
| Mar 31, 2024 | -445.63% |
| Dec 31, 2023 | -288.07% |
| Sep 30, 2023 | -183.29% |
| Jun 30, 2023 | -103.64% |
| Mar 31, 2023 | -89.84% |
| Dec 31, 2022 | -83.63% |
| Sep 30, 2022 | -99.64% |
| Jun 30, 2022 | -98.06% |
| Mar 31, 2022 | -94.73% |
| Dec 31, 2021 | -87.85% |
| Sep 30, 2021 | -108.75% |
| Jun 30, 2021 | -83.92% |